APOA5 Antikörper (N-Term)

Produktnummer ABIN965570

Der Kaninchen Polyklonal Anti-APOA5-Antikörper wurde für IHC validiert. Er ist geeignet, APOA5 in Proben von Human, Ratte und Maus zu detektieren.

Kurzübersicht für APOA5 Antikörper (N-Term) (ABIN965570)

Target: APOA5 (Apolipoprotein A-V (APOA5))

Reaktivität: Human, Ratte, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser APOA5 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC)

Produktdetails anti-APOA5 Antikörper

Bindungsspezifität: N-Term

Aufreinigung: Purified by antigen-specific affinity chromatography.

Immunogen: Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to N-terminal residues of human APOA5 (Apolipoprotein A-V precursor)

Anwendungsinformationen

Applikationshinweise: ELISA, Western blotting: 1µg/ml for 2hrs.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: This antibody is stored in PBS, 50% glycerol

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Details zu APOA5

Target: APOA5 (Apolipoprotein A-V (APOA5))

Andere Bezeichnung: APOA5

Hintergrund: APOA5(Apolipoprotein A-V) is a minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. APOA5 may also be associated with chylomicrons. APOA5 is an important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDLTG production rate (without affecting the VLDL-apoB production rate). Three common alleles are known: allele APOA5*1, APOA5*2 and APOA5*3. The APOA5*2 haplotype, which consists of 3 non-coding SNPs, is present in approximately 16% of Caucasians and is associated with increased plasma triglyceride concentrations. APOA5*3 haplotype is defined by the rare Ser-19-Trp substitution. Together, the APOA5*2 and APOA5*3 haplotypes are found in 25 to 50% of African Americans, Hispanics, and Caucasians.

Pathways: Regulation of Lipid Metabolism by PPARalpha, Lipid Metabolism